Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
13F holders, Q3 2025 (September 30)15holders −2
1new positions
3sold out
$0.95avg. 13F price*
At the end of Q3 2025, 15 institutions reported holding Biomarin Pharmaceutical (bmrn 1.25 05/15/27) in their 13F filings, down 2 from Q2 2025. 1 opened new positions and 3 sold out. The largest holders were Sonora Investment Management Group, LLC ($3.3M), State of Wisconsin Investment Board ($2.8M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.8M).
- Company
- Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
- CUSIP
- 09061GAK7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $10K |
| Exits | 3 | $13.9M |
All 13F filers, Q2 2025 → Q3 2025: 1,220,000 shares bought and 462,345 shares sold, net +757,655 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Sonora Investment Management Group, LLC | 0.24% | Reduce -4.5% | 3,480,000 | $3.3M |
| State of Wisconsin Investment Board | 0.01% | Add +50.0% | 3,000,000 | $2.8M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 2,900,000 | $2.8M |
| Bank of New York Mellon Corp | 0.00% | Add +66.7% | 500,000 | $475K |
| Sei Investments Co. | 0.00% | No change | 371,000 | $352K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +2.3% | 182,000 | $173K |
| Stephens Inc. | 0.00% | No change | 54,000 | $51K |
| Mariner, LLC | 0.00% | No change | 42,000 | $40K |
| &partners | 0.00% | Add +16.7% | 35,000 | $27K |
| Choreo, LLC | 0.00% | No change | 28,000 | $27K |
| Fifth Third Bancorp | 0.00% | New | 11,000 | $10K |
| DAVENPORT & Co LLC | 0.00% | No change | 10,000 | $9K |
| Cetera Investment Advisers | 0.00% | No change | 10,000 | $9K |
| Comerica Bank | 0.00% | No change | 9,000 | $9K |
| Oddo BHF Asset Management Sas | 0.00% | No change | 225 | $215 |
"% of holder's portfolio" is BIOMARIN PHARMACEUTICAL (BMRN 1.25 05/15/27)'s weight in each manager's 13F, not the share of Biomarin Pharmaceutical (bmrn 1.25 05/15/27) the manager owns.